NDA 065214 · B Braun
Cefoxitin and Dextrose In Duplex Container
Cefoxitin Sodium · Injection
Last checked: Nov 20, 2026Latest source record: Jul 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Mar 10, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
28
7 Phase 3, 2 recruiting
FAERS reports
204
177 serious, 21 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 29, 2019.
Cefoxitin for Injection and Dextrose Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible isolates of the designated bacteria ( 1 ): Lower respiratory tract infections ( 1.1 ); Urinary tract infections ( 1.2 ); Intra-abdominal infections ( 1.3 ); Gynecological infections ( 1.4 ); Septicemia ( 1.5 ); Bone and joint infections ( 1.6 ); Skin and skin structure infections ( 1.7 ); Prophylaxis ( 1.8 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefoxitin for Injection and Dextrose Injection and other antibacterial drugs, Cefoxitin for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.9 ). 1.1 Lower Respiratory Tract Infections Cefoxitin for Injection and Dextrose Injection is indicated for the treatment of lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae , and Bacteroides species. 1.2 Urinary Tract Infections Cefoxitin for Injection and Dextrose Injection is indicated for the treatment of urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). 1.3 Intra-abdominal Infections Cefoxitin for Injection and Dextrose Injection is indicated for the treatment of intra-abdominal infections , including peritonitis and intra-abdominal abscess, caused by...
Mechanism: Cefoxitin is an antibacterial drug [ see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 10, 2006 Original approval
2 products under this application
- CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER · CEFOXITIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER · CEFOXITIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Cefoxitin" as an intervention, any sponsor and status, largest first.
- Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal SurgeryPivotal-lookingStatus unknown
Poitiers University HospitalAcademic, hospital or other
NCT05755789 · 2,000 participants (planned) · Start Jun 22, 2023 · Primary completion May 2025
Drug: Loading bolus of cefoxitin; Intermittent cefoxitin and 3 more · For: Antibiotic Prophylaxis; Colorectal Surgery
Sites: Poitiers, France; Angers, France; Arras, France · 19 sites in all
- The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) TrialPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT02800785 · 1,552 participants · Start May 2016 · Primary completion Mar 5, 2020
Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin · For: Appendicitis
Sites: Sylmar, California; Torrance, California; Aurora, Colorado · 25 sites in all
- Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive WomenPivotal-lookingCompleted
University of KwaZuluAcademic, hospital or other
NCT00343317 · 1,372 participants · Start Feb 2003
Drug: Intrapartum Cefoxitin (2g) vs. placebo · For: Puerperal Sepsis
Sites: Durban, South Africa
- Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?Pivotal-lookingCompleted
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT03269994 · 967 participants · Start Nov 21, 2017 · Primary completion Jan 28, 2025
Drug: Cefoxitin; Piperacillin-tazobactam · For: Pancreatic Cancer; Pancreas Cancer; Pancreatic Diseases
Sites: Sacramento, California; Atlanta, Georgia; Chicago, Illinois · 32 sites in all
- Two-drug Antibiotic Prophylaxis in Scheduled Cesarean DeliveriesPivotal-lookingStatus unknown
RWJ Barnabas Health at Jersey City Medical CenterAcademic, hospital or other
NCT03960970 · 800 participants (planned) · Start Sep 15, 2019 · Primary completion Sep 30, 2019
Drug: Azithromycin 500 mg; Mefoxin 2g · For: Endometritis; Cesarean Section; Infection; Wound Infection
Sites: Jersey City, New Jersey
- Immediate Versus Delayed Induction in Term-PROM Using or Not Antibiotic ProphylaxisPivotal-lookingStatus unknown
Hospital de Santa Maria, PortugalAcademic, hospital or other
NCT02985086 · 568 participants (planned) · Start Jul 2013 · Primary completion Jul 2018
Drug: Cefoxitin; oxytocin/misoprostol · For: Maternal Infection During Pregnancy (Diagnosis); Neonatal Infection
Sites: Almada, Portugal; Lisbon, Portugal
- Duration of Perioperative Antibiotics in PancreatoduodenectomyPivotal-lookingEnrolling by invitation
Asan Medical CenterAcademic, hospital or other
NCT07043855 · 558 participants (planned) · Start May 11, 2026 · Primary completion Oct 2028
Drug: single dose preoperative antibiotic; Prolonged perioperative antibiotics · For: Pancreatoduodenectomy; PPPD; Infectious Complications
Sites: Seoul, South Korea
- Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction PatientPivotal-lookingStatus unknown
Yonsei UniversityAcademic, hospital or other
NCT02958059 · 400 participants (planned) · Start Dec 1, 2016 · Primary completion Aug 2020
Drug: Pacetin® (cefoxitin); Placebo · For: Biliary Obstructive Disease Such as Choledocholithiasis; Benign Biliary Stricture; Peri-ampullary Cancer and 2 more
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use19
- rash13
- drug hypersensitivity12
- anaphylactic shock11
- nausea11
- pneumonia11
- thrombocytopenia11
- diarrhoea10
- acute kidney injury9
- leukopenia9
- platelet count decreased9
- pyrexia9
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 6 |
| 2016 | 18 |
| 2017 | 15 |
| 2018 | 22 |
| 2019 | 22 |
| 2020 | 8 |
| 2021 | 12 |
| 2022 | 11 |
| 2023 | 22 |
| 2024 | 28 |
| 2025 | 8 |
| 2026 | 10 |
Recalls
1 FDA enforcement reports for this application.
Nov 21, 2013 · Class I · Terminated
Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomized clinical trial of perioperative cefoxitin in preventing maternal infection after primary cesarean section.
Polk BF, Krache M, Phillippe M, et al. · Am J Obstet Gynecol 1982 · Clinical Trial, Comparative Study
- Single- versus three-dose cefoxitin prophylaxis in caesarean section: a randomized clinical trial.
Roex AJ, Puyenbroek JI, van Loenen AC, et al. · Eur J Obstet Gynecol Reprod Biol 1987 · Clinical Trial, Randomized Controlled Trial
- A randomized clinical trial of antibiotic prophylaxis in cesarean section: maternal morbidity, risk factors and bacteriological changes.
Roex AJ, Puyenbroek JI, MacLaren DM, et al. · Eur J Obstet Gynecol Reprod Biol 1986 · Clinical Trial, Randomized Controlled Trial
- Clinical trial of cefoxitin (mefoxin) in parenteral therapy of septicemia (postabortal and postpartum) in Ibadan.
Adelusi B, Osoba AO, Adetoro OA, et al. · Afr J Med Med Sci 1985 · Clinical Trial, Controlled Clinical Trial
- Intramuscular cefoxitin.
McCloskey RV · Rev Infect Dis 1979 · Clinical Trial, Research Support, Non-U.S. Gov't
- Cefoxitin single dose prophylaxis and/or T tube suction drainage for vaginal and abdominal hysterectomy (Prospective randomized trial on 155 patients).
Scotto V, Sbiroli C · Clin Exp Obstet Gynecol 1985 · Clinical Trial, Randomized Controlled Trial
Sponsor: B Braun
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.